List Thomas, Neri Dario
Department of Chemistry and Applied Biosciences, Swiss Federal institute of Technology (ETH Zürich), Zurich, Switzerland.
Clin Pharmacol. 2013 Aug 20;5(Suppl 1):29-45. doi: 10.2147/CPAA.S49231. eCollection 2013.
The concept of therapeutically enhancing the immune system's responsiveness to tumors is long standing. Several cytokines have been investigated in clinical trials for their therapeutic activity in cancer patients. However, substantial side effects and unfavorable pharmacokinetic properties have been a major drawback hampering the administration of therapeutically relevant doses. The use of recombinant antibody-cytokine fusion proteins promises to significantly enhance the therapeutic index of cytokines by targeting them to the site of disease. This review aims to provide a concise and complete overview of the preclinical data and clinical results currently available for all immunocytokines having reached clinical development.
通过治疗手段增强免疫系统对肿瘤的反应性这一概念由来已久。几种细胞因子已在临床试验中针对其在癌症患者中的治疗活性进行了研究。然而，严重的副作用和不良的药代动力学特性一直是阻碍给予治疗相关剂量的主要障碍。使用重组抗体 - 细胞因子融合蛋白有望通过将细胞因子靶向疾病部位来显著提高其治疗指数。本综述旨在对目前已进入临床开发阶段的所有免疫细胞因子的临床前数据和临床结果提供简明而全面的概述。
